NCT06035497 2026-04-06A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Bristol-Myers SquibbPhase 1/2 Active not recruiting85 enrolled
NCT05909527 2026-03-17A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ LymphomaGuangzhou Bio-gene Technology Co., LtdPhase 1/2 Withdrawn
NCT07471789 2026-03-13Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala TherapeuticsPhase 1/2 Recruiting33 enrolled
NCT05170828 2026-02-24Cryopreserved MMUD BM With PTCy for Hematologic MalignanciesOssium Health, Inc.Phase 1 Withdrawn
NCT04817761 2026-02-18SPARK-ALL: Calaspargase Pegol in Adults With ALLServierPhase 2/3 Terminated42 enrolled
NCT06761677 2026-02-05A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSymBio PharmaceuticalsPhase 1/2 Suspended43 enrolled